These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
tatiomycin_crx_submission.pdf (414.74 kB)

Discovery of the Antibiotic Polyketide Tatiomicin via a Genomics Guided Analysis of Amycolatopsis sp. DEM30355

submitted on 10.12.2020, 16:34 and posted on 14.12.2020, 05:05 by Bernhard Kepplinger, Joseph Cowell, Stephanie Morton-Laing, Corinne Wills, Emma Marrs, John Perry, Joe Grey, Michael Goodfellow, Jeff Errington, Michael Probert, Bill Clegg, Jonathan Bogaerts, Wouter Herrebout, Nick E. E. Allenby, Michael Hall
The application of genomic techniques to the investigation of understudied species of actinobacteria provides an expedited route to the discovery of new bioactive natural products. We report the isolation of the antibiotic polyketide tatiomicin, through a genomics and bioactivity informed analysis of the metabolome of the extremophile Amycolatopsis sp. DEM30355. Structural elucidation including absolute stereochemical assignment was performed using complementary crystallographic, spectroscopic and computational methods. Tatiomicin shows antibiotic activity against Gram-positive bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA).


Industrial Doctorate Centre: Biopharmaceutical Process Development

Engineering and Physical Sciences Research Council

Find out more...

The Development and Commercialisation of Novel Antibiotic Compounds

Innovate UK

Find out more...

Natural Product Antibiotics for multi-drug resistant pathogens

Innovate UK

Find out more...


Email Address of Submitting Author


Newcastle University


United Kingdom

ORCID For Submitting Author


Declaration of Conflict of Interest

NEEA/Demuris have filed a patent on tatiomicin

Version Notes

version 1.0